ACKNOWLEDGEMENTS
Funding/Support: This work was supported in part by the Cancer Prevention & Research Institute of Texas (CPRIT RP170071), the Canadian Institutes for Health Research Foundation Scheme Grant (#143234), Terry Fox Research Institute New Frontiers Program Project (#1081), and the St. Baldrick’s Foundation. This work was also supported by grants from the WWWW (QuadW) Foundation, the Children’s Oncology Group Foundation, the Isabella Santos Foundation, and by U10CA098543, U10CA098413, U10CA180899, and U10CA180886 from the National Cancer Institute to the Children’s Oncology Group. This work is also supported by Hyundai Hope on Wheels, Soccer for Hope Foundation, Li-Fraumeni Syndrome Association, Kneaders Bakery & Café Hope Campaign, 5 For The Fight (Qualtrics), and the Elephant p53 (EP53) Program funded through Huntsman Cancer Institute by the State of Utah.
REFERENCES
1. Li J, Thompson TD, Miller JW, Pollack LA, Stewart SL. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics . Jun 2008;121(6):e1470-7. doi:10.1542/peds.2007-2964
2. Li FP, Fraumeni JF, Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst . Dec 1969;43(6):1365-73.
3. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.Science . Nov 30 1990;250(4985):1233-8. doi:10.1126/science.1978757
4. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations.Nat Genet . May 1994;7(1):91-7. doi:10.1038/ng0594-91
5. Hettmer S, Archer NM, Somers GR, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer . Apr 1 2014;120(7):1068-75. doi:10.1002/cncr.28507
6. Bougeard G, Renaux-Petel M, Flaman JM, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol . Jul 20 2015;33(21):2345-52. doi:10.1200/jco.2014.59.5728
7. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2020). Accessed August 1, 2020, https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf
8. Li H, Sisoudiya SD, Martin-Giacalone BA, et al. Germline Cancer-Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report from the Children’s Oncology Group. J Natl Cancer Inst . Dec 29 2020;doi:10.1093/jnci/djaa204
9. Kodet R, Newton WA, Jr., Hamoudi AB, Asmar L, Jacobs DL, Maurer HM. Childhood rhabdomyosarcoma with anaplastic (pleomorphic) features. A report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol . May 1993;17(5):443-53. doi:10.1097/00000478-199305000-00002
10. Qualman S, Lynch J, Bridge J, et al. Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group.Cancer . Dec 1 2008;113(11):3242-7. doi:10.1002/cncr.23929
11. Pondrom M, Bougeard G, Karanian M, et al. Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience. Pediatr Blood Cancer . Jul 13 2020:e28486. doi:10.1002/pbc.28486
12. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest . Apr 1995;95(4):1606-11. doi:10.1172/jci117834
13. Brodeur GM, Nichols KE, Plon SE, Schiffman JD, Malkin D. Pediatric Cancer Predisposition and Surveillance: An Overview, and a Tribute to Alfred G. Knudson Jr. Clinical Cancer Research . 2017;23(11):e1-e5. doi:10.1158/1078-0432.Ccr-17-0702